Complement in Lupus: Biomarker, Therapeutic Target, or a Little Bit of Both?
Authors:
Open Access
- 1 August 2021
- journal article
- editorial
- Published by Elsevier in Kidney International Reports
- Vol. 6 (8) , 2031-2032
Abstract
No abstract availableFunding Information
- National Institute of Allergy and Infectious Diseases (R01 AI132949)
This publication has 9 references indexed in Scilit:
- The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its FlareKidney International Reports, 2021
- Expanding the Role of Complement Therapies: The Case for Lupus NephritisJournal of Clinical Medicine, 2021
- Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosisJournal of Experimental Medicine, 2020
- A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathyBMC Nephrology, 2020
- New insights into the immunopathogenesis of systemic lupus erythematosusNature Reviews Rheumatology, 2016
- Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical PathwayFrontiers in Immunology, 2016
- Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid ArthritisThe Journal of Immunology, 2015
- C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/ReperfusionThe Journal of Immunology, 2007
- Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.Proceedings of the National Academy of Sciences, 1996